Safety and Tolerability of Second and
Third Generation Antipsychotics
Češková E., Novotný T.1, Floriánová A.2, Pálenský V.
Psychiatrická klinika LF MU a FN, Brno, přednosta prof. MUDr. E. Češková, CSc. Kardiologická klinika LF MU a FN, Brno, přednosta prof. MUDr. J. Špinar, CSc. |
|
Summary:
At first the authors deal with new antipsychotics. In the centre of interest there are new antipsychotics,
often referred to as atypical or antipsychotics of the second or third generation. The atypical
antipsychotics carry less risk or EPS, however, they can cause other side effects. These can be a problem,
because schizophrenic patients have higher rate of morbidity and mortality from cardiovascular
disease independent from treatment. These side effects include weight gain, diabetes, hyperlipidemia
and QT prolongation. The published data concerning this topic are summarized. Finally
the data concerning the QT prolongation in unselected population of hospitalised psychiatric patients
at Brno psychiatric department are presented. The occurrence (4.1 % of patients) of abnormal
QTc was lower than in the so-far available literature. This could be connected with the change of
spectrum of antipsychotics used, the general trend to use lower doses of antipsychotics and prescribers
increasing awareness about this phenomenon.
Key words:
second and third generation antipsychotics, extrapyramidal side effects, morbidity, mortality,
prolongation of QT interval.
|